- Third-Quarter 2014 Non-GAAP EPS of
$0.90, Excluding Certain Items, and GAAP EPS of $0.31
- Narrows 2014 Full-Year Non-GAAP EPS
Target to $3.46 to $3.50, Excluding Certain Items; Updates 2014
Full-Year GAAP EPS Target to $4.06 to $4.29; Now Expects 2014
Full-Year Revenues to be Between $42.4 Billion and $42.8
Billion
- Generated Worldwide Sales of $10.6
Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of
Divested Products, Patent Expiries and Decline in Sales of
Hepatitis C Products
- Increased Sales of Acute Care,
Immunology, Diabetes and Animal Health Products
- FDA Approved KEYTRUDA for the Treatment
of Advanced Melanoma in Patients Who Have Progressed after Other
Therapies and BELSOMRA for the Treatment of Insomnia
- KEYTRUDA Received Breakthrough Therapy
Designation from the FDA for Patients with Advanced Non-Small Cell
Lung Cancer Who Have Progressed Following Platinum-Containing
Chemotherapy
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced financial results for the third quarter of
2014.
Third Quarter Third Quarter $ in
millions, except EPS amounts
2014 2013
Sales $10,557 $11,032 GAAP EPS 0.31
0.38
Non-GAAP EPS that excludes items listed
below1
0.90 0.92
GAAP Net Income2
895 1,124 Non-GAAP Net Income that excludes items
listed below1,2 2,617 2,729
Non-GAAP (generally accepted accounting principles) earnings per
share (EPS) for the third quarter of $0.90 exclude acquisition- and
divestiture-related costs, restructuring costs and certain other
items.
A reconciliation of GAAP to non-GAAP net income and EPS is
provided in the tables that follow. Year-to-date results can be
found in the attached tables.
$ in millions, except EPS amounts
Third Quarter 2014
Third Quarter 2013 EPS
GAAP EPS $0.31 $0.38
Difference3
0.59 0.54 Non-GAAP EPS that excludes items listed
below1 $0.90 $0.92
Net Income
GAAP net income2 $895 $1,124
Difference 1,722 1,605 Non-GAAP net income that
excludes items listed below1,2 $2,617 $2,729
Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition- and divestiture-related
costs4
$1,659 $1,196 Restructuring costs 612
967 Additional year of health care reform fee 193 --
Gain on divestiture of certain ophthalmic products (396)
-- Other 5 -- Net decrease (increase) in
income before taxes 2,073 2,163
Income tax (benefit) expense5
(295) (558) Acquisition- and divestiture-related
costs attributable to non-controlling interests (56)
-- Decrease (increase) in net income2 $1,722 $1,605
“Last October, we launched a multi-year initiative to transform
Merck and build a platform for sustained, future growth,” said
Kenneth C. Frazier, chairman and chief executive officer, Merck.
“One year later, we delivered solid third-quarter results and are
making steady progress in our transformation, including divesting
non-core assets, reducing our expense base and investing in our
promising new product launches and pipeline.”
Select Revenue Highlights
Worldwide sales were $10.6 billion for the third quarter of
2014, a decrease of 4 percent compared with the third quarter of
2013, including a 1 percent positive impact from foreign exchange.
The decline includes $425 million of lower sales due to
divestitures and the termination of the joint venture with
AstraZeneca (AZ).
The following table reflects sales of the company’s top
pharmaceutical products, as well as total sales of Animal Health
and Consumer Care products.
Third Quarter Third Quarter
Change Change $ in millions
2014 2013
Ex-exchange Total Sales $10,557 $11,032
-4% -5% Pharmaceutical 9,134 9,475 -4% -4%
JANUVIA/JANUMET 1,439 1,369 5% 5%
ZETIA/VYTORIN 1,028 1,059 -3% -3% REMICADE
604 574 5% 3% GARDASIL 590 665
-11% -11% PROQUAD, M-M-R II and VARIVAX 421
421 0% 0% ISENTRESS 412 427 -3% -3%
NASONEX 261 297 -12% -12% SINGULAIR 218
280 -22% -20% Animal Health 885 800
11% 10% Consumer Care 401 443 -9% -9%
Other Revenues 137 314 -56% -71%
Pharmaceutical Revenue Performance
Third-quarter pharmaceutical sales declined 4 percent to $9.1
billion. Expected declines occurred due to the ongoing impact of
product divestitures, as well as the loss of market exclusivity for
certain products, including TEMODAR (temozolomide) and SINGULAIR
(montelukast sodium). Also contributing to the decline were lower
sales from the hepatitis franchise of VICTRELIS (boceprevir) and
PEGINTRON (peginterferon alfa-2b) as a result of increased
competition, as well as of GARDASIL [Human Papillomavirus
Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]. These
declines were partially offset by growth in the global acute care
franchise, including NOXAFIL (posaconazole) and BRIDION
(sugammadex); the diabetes franchise of JANUVIA
(sitagliptin)/JANUMET (sitagliptin and metformin HCI); REMICADE
(infliximab); SIMPONI (golimumab); and DULERA (mometasone furoate
and formoterol fumarate dihydrate).
Combined sales of JANUVIA and JANUMET, medicines that help lower
blood sugar levels in adults with type 2 diabetes, grew 5 percent
to $1.4 billion in the third quarter. The growth reflects higher
sales in the United States and Europe, which were partially offset
by price reductions in Japan.
Combined sales of ZETIA (ezetimibe) and VYTORIN
(ezetimibe/simvastatin), medicines for lowering LDL cholesterol,
declined 3 percent to $1.0 billion in the third quarter, driven by
lower sales in the United States.
Combined sales of REMICADE and SIMPONI, treatments for
inflammatory diseases, grew 11 percent to $774 million in the third
quarter, including a 2 percent positive impact from foreign
exchange. Over the last 12 months, SIMPONI has been the fastest
growing anti-TNF agent in all countries where marketed by
Merck.
Merck’s sales of GARDASIL, a vaccine to help prevent certain
diseases caused by four types of human papillomavirus, were $590
million, a decrease of 11 percent for the third quarter. The
results reflect lower purchases in the U.S. public sector.
Worldwide sales of ISENTRESS, an HIV integrase inhibitor for use
in combination with other antiretroviral agents for the treatment
of HIV-1 infection, decreased 3 percent to $412 million in the
third quarter. The decline reflects lower sales in the United
States, partially offset by growth in Europe.
On Sept. 4, 2014, the U.S. Food and Drug Administration (FDA)
granted accelerated approval of KEYTRUDA (pembrolizumab), the first
approved anti-PD-1 therapy in the United States. KEYTRUDA has been
approved for the treatment of patients with unresectable or
metastatic melanoma and disease progression following ipilimumab
and, if BRAF V600 mutation positive, a BRAF inhibitor. Within a few
days of approval, initial orders shipped, and the Merck team has
already reached more than 75 percent of key physicians. Merck
believes there are currently approximately 1,200 patients who may
be eligible for KEYTRUDA, based on the product’s label, and to
date, approximately 900 patients are being treated with
KEYTRUDA.
Animal Health Revenue Performance
Animal Health sales totaled $885 million for the third quarter
of 2014, an increase of 11 percent compared with the third quarter
of 2013, including a 1 percent positive impact due to foreign
exchange. Growth was driven by increases across all species. In
companion animals, growth was supported by ongoing launches in
Europe and the United States of BRAVECTO (fluralaner), a chewable
tablet that kills fleas and ticks in dogs for up to 12 weeks.
Growth was partially offset by the loss of sales of ZILMAX
(zilpaterol hydrochloride), a feed supplement for beef cattle. The
company decided last year to voluntarily suspend sales of ZILMAX in
the United States and Canada. Excluding the impact of the ZILMAX
sales suspension, Animal Health sales increased 14 percent in the
third quarter.
Consumer Care Revenue Performance
Third-quarter global sales of Consumer Care products were $401
million, a decline of 9 percent compared to the third quarter of
2013. As previously announced, Merck completed the sale of its
Consumer Care business to Bayer AG on Oct. 1, 2014.
Other Revenue Performance
Other revenues – primarily comprising alliance revenue,
miscellaneous corporate revenues and third-party manufacturing
sales – decreased 56 percent to $137 million compared to the third
quarter of 2013. The decrease was driven primarily by the loss of
revenue from AZ recorded by Merck, which was $220 million in the
third quarter of 2013. On June 30, 2014, AZ exercised its option to
buy the company’s interest in a subsidiary and, through it, the
company’s interest in Nexium and Prilosec. As of July 1, 2014,
Merck no longer records equity income from AZ and supply sales to
AZ have ended. The decline in other revenues also reflects $50
million of lower third-party manufacturing sales, primarily driven
by the divestiture of a substantial portion of this business in
2013.
Third-Quarter Expense and Other Information
The costs detailed below totaled $9.2 billion on a GAAP basis
during the third quarter of 2014 and include $2.4 billion of
acquisition- and divestiture-related costs, restructuring costs and
certain other items.
$ in millions
Included in expenses for the period
Acquisition- and
Restructuring GAAP Divestiture- Costs
Certain Non-GAAP(1) Third Quarter
Related Other Items 2014
Costs(4) Materials
and production $4,223 $1,420 $87 $--
$2,716 Marketing and administrative 2,975 110
68 193 2,604 Research and development
1,659 36 81 -- 1,542 Restructuring
costs 376 -- 376 -- --
Third Quarter 2013
Materials and production
$4,104 $1,176 $57 $-- $2,871 Marketing
and administrative 2,803 20 31 --
2,752 Research and development 1,660 --
9 -- 1,651 Restructuring costs 870 --
870 -- --
The gross margin was 60.0 percent for the third quarter of 2014
compared to 62.8 percent for the third quarter of 2013, reflecting
14.3 and 11.2 unfavorable percentage point impacts, respectively,
from the acquisition- and divestiture-related costs, and
restructuring costs noted above.
Marketing and administrative expenses, on a non-GAAP basis, were
$2.6 billion in the third quarter of 2014, a decrease primarily due
to productivity measures from $2.8 billion in the same period of
2013.
Research and development (R&D) expenses, on a non-GAAP
basis, were $1.5 billion in the third quarter of 2014, a decrease
from $1.7 billion in the third quarter of 2013. The decline
reflects targeted cost reductions and lower clinical development
spending resulting from portfolio prioritization.
Other (income) expense, net, was $142 million of income in the
third quarter of 2014 compared to $172 million of expense in the
third quarter of 2013. The third quarter of 2014 includes a gain of
$396 million on the divestiture of certain ophthalmic products in
several international markets, partially offset by a $93 million
goodwill impairment charge related to the company’s joint venture
with Supera Farma Laboratorios S.A. in Brazil.
The GAAP effective tax rate of 43.5 percent for the third
quarter of 2014 reflects the impacts of acquisition- and
divestiture-related costs, restructuring costs and certain other
items, including an additional year of expense related to the
non-tax deductible health care reform fee. The non-GAAP effective
tax rate, which excludes these items, was 26.5 percent for the
quarter.
Key Developments
- The FDA granted accelerated approval of
KEYTRUDA on Sept. 4, 2014, for the treatment of advanced melanoma
in patients who have progressed after other therapies.
- As announced earlier today, KEYTRUDA
received Breakthrough Therapy Designation from the FDA for patients
with advanced non-small cell lung cancer who have progressed
following platinum-containing chemotherapy.
- Interim data in five tumor types
exploring investigational uses of KEYTRUDA was presented at the
2014 European Society for Medical Oncology 2014 Congress.
- On Aug. 13, 2014, the FDA approved
BELSOMRA (suvorexant) for the treatment of adults with insomnia who
have difficulty falling asleep and/or staying asleep.
- Merck completed the sale of its
Consumer Care business to Bayer AG on Oct. 1, 2014. As previously
announced, the companies have entered into a worldwide
collaboration to develop and commercialize soluble guanylate
cyclase modulators. The collaboration includes Bayer’s Adempas
(riociguat), which is approved to treat pulmonary arterial
hypertension and chronic thromboembolic pulmonary
hypertension.
- On Aug. 5, 2014, Merck completed its
acquisition of Idenix Pharmaceuticals, Inc. to expand its portfolio
of investigational therapies for hepatitis C.
- On Oct. 15, 2014, the company announced
that it accepted for purchase $1.8 billion in principal amount of
eight series of notes as part of a previously announced tender
offer. In addition, the company intends to redeem its $1.0 billion
4% Notes due 2015 and its $1.0 billion 6% Senior Notes due 2017. As
a result of these transactions, Merck expects to record a pre-tax
charge of approximately $650 million in the fourth quarter of 2014,
which will be excluded from non-GAAP results.
For a full listing of company developments that occurred in the
third quarter of 2014, visit the newsroom at www.merck.com.
Financial Outlook
Merck has narrowed its full-year 2014 non-GAAP EPS range to be
between $3.46 and $3.50. The range excludes acquisition- and
divestiture-related costs and costs related to restructuring
programs, as well as certain other items. Merck now expects the
company’s full-year 2014 GAAP EPS range to be between $4.06 and
$4.29.
At current exchange rates, Merck now anticipates full-year 2014
revenues to be between $42.4 billion and $42.8 billion.
In addition, the company continues to expect full-year 2014
non-GAAP marketing and administrative and R&D expenses will be
below 2013 levels. In the fourth quarter of 2014, the company
anticipates R&D expenses will be higher than the fourth quarter
of 2013 due to timing of certain programs. The company continues to
anticipate its full-year 2014 non-GAAP tax rate will be in the
range of 24 to 26 percent, not including a 2014 R&D tax
credit.
A reconciliation of anticipated 2014 EPS, as reported in
accordance with GAAP to non-GAAP EPS that excludes certain items,
is provided in the table below.
Full Year $ in millions, except EPS amounts
2014 GAAP EPS $4.06 to $4.29 Difference3
(0.60) to (0.79) Non-GAAP EPS that excludes items listed below
$3.46 to $3.50 Acquisition- and
divestiture-related costs $5,700 to $5,500 Restructuring
costs 1,700 to 1,500 Loss on extinguishment of debt
675 to 625 Additional year of health care reform fee 193
Gain on AZ option exercise (741) Gain on divestiture of
certain ophthalmic products (490) to (510) Gain on sale of
Merck Consumer Care (11,000) to (11,300) Net decrease
(increase) in income before taxes (3,963) to (4,733)
Estimated income tax (benefit) expense 2,250 to 2,475
Decrease (increase) in net income (1,713) to (2,258)
Acquisition- and divestiture-related costs attributable to
non-controlling interests (56) Decrease (increase) in net
income2 ($1,769) to ($2,314)
Total Employees
As of Sept. 30, 2014, Merck had approximately 71,000 employees
worldwide. In addition, the company’s joint ventures in China and
Brazil, which are included in the consolidated results of Merck,
had about 1,200 employees.
Earnings Conference Call
Investors, journalists and the general public may access a live
audio webcast of the call today at 8:00 a.m. EDT on Merck’s website
at
http://www.merck.com/investors/events-and-presentations/home.html.
Institutional investors and analysts can participate in the call by
dialing (706) 758-9927 or (877) 381-5782 and using ID code number
5243903. Members of the media are invited to monitor the call by
dialing (706) 758-9928 or (800) 399-7917 and using ID code number
5243903. Journalists who wish to ask questions are requested to
contact a member of Merck’s Media Relations team at the conclusion
of the call.
About Merck
Today’s Merck is a global healthcare leader working to help the
world be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access
to healthcare through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com and connect
with us on Twitter, Facebook and YouTube. You can also follow our
Twitter conversation at $MRK.
Forward-Looking Statement
This news release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of Merck’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in Merck’s 2013 Annual
Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
###
1 Merck is providing certain 2014 and 2013 non-GAAP information
that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s
performance. This information should be considered in addition to,
but not in lieu of, information prepared in accordance with GAAP.
For description of the items, see Table 2a, including the related
footnotes, attached to this release.
2 Net income attributable to Merck & Co., Inc.
3 Represents the difference between calculated GAAP EPS and
calculated non-GAAP EPS, which may be different than the amount
calculated by dividing the impact of the excluded items by the
weighted-average shares for the period.
4 Includes expenses of $1.0 billion and $1.2 billion in the
third quarter of 2014 and 2013, respectively, for the amortization
of intangible assets recognized as a result of mergers and
acquisitions, as well as intangible asset impairment charges of
$541 million in the third quarter of 2014. Also includes merger
integration costs, as well as transaction and certain other costs
related to business acquisitions and divestitures.
5 Includes the estimated tax impact on the reconciling
items.
MERCK & CO., INC. CONSOLIDATED STATEMENT OF
INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE
FIGURES) (UNAUDITED) Table 1
GAAP %
Change GAAP % Change
3Q14 3Q13 Sep YTD 2014 Sep
YTD 2013
Sales $ 10,557 $ 11,032 -4% $ 31,755 $ 32,713 -3% Costs,
Expenses and Other Materials and production (1) 4,223 4,104 3%
13,019 12,347 5% Marketing and administrative (1) 2,975 2,803 6%
8,681 8,929 -3% Research and development (1) 1,659 1,660 -- 4,897
5,668 -14% Restructuring costs (2) 376 870 -57% 664 1,144 -42%
Equity income from affiliates (3) (24 ) (102 ) -76% (241 ) (351 )
-31% Other (income) expense, net (1) (4) (142 ) 172 * (737 ) 656 *
Income Before Taxes 1,490 1,525 -2% 5,472 4,320 27% Income Tax
Provision 648 375 865 618 Net Income 842 1,150 -27% 4,607 3,702 24%
Less: Net (Loss) Income Attributable to Noncontrolling Interests
(53 ) 26 3 79 Net Income Attributable to Merck & Co., Inc. $
895 $ 1,124 -20% $ 4,604 $ 3,623 27% Earnings per Common Share
Assuming Dilution $ 0.31 $ 0.38 -18% $ 1.57
$ 1.20 31%
Average Shares Outstanding Assuming Dilution 2,911 2,960
2,942 3,007 Tax Rate (5) 43.5 % 24.6 %
15.8 % 14.3 %
* 100% or greater
(1) Amounts include the impact of acquisition and
divestiture-related costs, restructuring costs and certain other
items. See accompanying tables for details.
(2) Represents separation and other related costs associated
with restructuring activities under the company's formal
restructuring programs.
(3) Reflects the performance of the company’s joint ventures and
other equity method affiliates, including the Sanofi Pasteur MSD
partnership, as well as the AstraZeneca LP partnership until its
termination on June 30, 2014.
(4) Other (income) expense, net in the third quarter and first
nine months of 2014 includes a gain of $396 million on the
divestiture of certain ophthalmic products in several international
markets, partially offset by a $93 million goodwill impairment
charge related to the company's joint venture with Supera Farma
Laboratorios S.A. Other (income) expense, net in the first nine
months of 2014 also includes a gain of $741 million related to
AstraZeneca's option exercise and net gains of $168 million related
to the divestiture of the company's Sirna Therapeutics, Inc.
subsidiary. Other (income) expense, net in the first nine months of
2013 reflects approximately $140 million of exchange losses as a
result of a Venezuelan currency devaluation.
(5) The effective income tax rate for the first nine months of
2014 reflects a net benefit of $517 million recorded in connection
with AstraZeneca's option exercise, as well as a benefit of
approximately $300 million associated with a capital loss generated
in the first quarter of 2014.
The effective income tax rate for the first nine months of 2013
reflects net benefits from the settlements of certain federal
income tax issues, reductions in tax reserves upon expiration of
applicable statute of limitations and the favorable impact of tax
legislation enacted in the first quarter of 2013.
MERCK & CO., INC. CONSOLIDATED STATEMENT OF
INCOME GAAP TO NON-GAAP RECONCILIATION THIRD QUARTER
2014 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED) Table 2a
Acquisition and Restructuring Certain Other
Adjustment GAAP Divestiture-
Costs (2)
Items (3)
Subtotal Non-GAAP
Related Costs (1)
Sales
$
10,557 $ 10,557 Costs, Expenses and Other Materials
and production
4,223 1,420 87 1,507 2,716 Marketing and
administrative
2,975 110 68 193 371 2,604 Research and
development
1,659 36 81 117 1,542 Restructuring costs
376 376 376 - Equity income from affiliates
(24
) (24 ) Other (income) expense, net
(142 ) 93
(391 ) (298 ) 156 Income Before Taxes
1,490 (1,659 ) (612 )
198 (2,073 ) 3,563 Taxes on Income
648 (295 )
(4)
943 Net Income
842 (1,778 ) 2,620 Less: Net (Loss) Income
Attributable to Noncontrolling Interests
(53 ) (56 )
(56 ) 3 Net Income Attributable to Merck & Co., Inc.
$
895 $ (1,722 ) $ 2,617 Earnings per Common Share Assuming
Dilution
$ 0.31 $ 0.90
Average Shares Outstanding Assuming Dilution
2,911 2,911 Tax
Rate
43.5 % 26.5 %
Merck is providing non-GAAP information that excludes certain
items because of the nature of these items and the impact they have
on the analysis of underlying business performance and trends.
Management believes that providing this information enhances
investors' understanding of the company's performance. This
information should be considered in addition to, but not in lieu
of, information prepared in accordance with GAAP.
(1) Amounts included in materials and production costs reflect
expenses of $1.0 billion for the amortization of intangible assets
recognized as a result of mergers and acquisitions, as well as $412
million of impairment charges on product intangibles. Amounts
included in marketing and administrative expenses reflect merger
integration costs, as well as transaction and certain other costs
related to business acquisitions and divestitures. Amounts included
in research and development expenses represent in-process research
and development (“IPR&D”) impairment charges primarily related
to the company's joint venture with Supera. Amount included in
other (income) expense, net represents a goodwill impairment charge
related to the joint venture with Supera. Amount included in net
(loss) income attributable to non-controlling interests represents
the portion of intangible asset and goodwill impairment charges
related to the joint venture with Supera that are attributable to
non-controlling interests.
(2) Amounts primarily include employee separation costs and
accelerated depreciation associated with facilities to be closed or
divested related to actions under the company's formal
restructuring programs.
(3) Amount included in marketing and administrative expenses
represents an additional year of expense related to the healthcare
reform fee in accordance with final regulations issued in the third
quarter by the Internal Revenue Service. Included in other (income)
expenese, net is a $396 million gain on the divestiture of certain
ophthalmic products in several international markets.
(4) Represents the estimated tax impact on the reconciling
items.
MERCK & CO., INC. CONSOLIDATED STATEMENT OF
INCOME GAAP TO NON-GAAP RECONCILIATION NINE MONTHS
ENDED SEPTEMBER 30, 2014 (AMOUNTS IN MILLIONS, EXCEPT PER
SHARE FIGURES) (UNAUDITED) Table 2b
Acquisition and Restructuring
Certain Other Adjustment GAAP
Divestiture-
Costs (2)
Items (3)
Subtotal Non-GAAP
Related Costs (1)
Sales
$
31,755 $ 31,755 Costs, Expenses and Other Materials
and production
13,019 4,270 377 4,647 8,372 Marketing and
administrative
8,681 153 143 193 489 8,192 Research and
development
4,897 36 175 211 4,686 Restructuring costs
664 664 664 - Equity income from affiliates
(241
) (241 ) Other (income) expense, net
(737 ) 93
(1,132 ) (1,039 ) 302 Income Before Taxes
5,472 (4,552 )
(1,359 ) 939 (4,972 ) 10,444 Taxes on Income
865 (1,809 )
(4)
2,674 Net Income
4,607 (3,163 ) 7,770 Less: Net Income
(Loss) Attributable to Noncontrolling Interests
3 (56 ) (56
) 59 Net Income Attributable to Merck & Co., Inc.
$
4,604 $ (3,107 ) $ 7,711 Earnings per Common Share Assuming
Dilution
$ 1.57 $ 2.62
Average Shares Outstanding Assuming Dilution
2,942 2,942 Tax
Rate
15.8 % 25.6 %
Merck is providing non-GAAP information that excludes certain
items because of the nature of these items and the impact they have
on the analysis of underlying business performance and trends.
Management believes that providing this information enhances
investors' understanding of the company's performance. This
information should be considered in addition to, but not in lieu
of, information prepared in accordance with GAAP.
(1) Amounts included in materials and production costs reflect
expenses of $3.2 billion for the amortization of intangible assets
recognized as a result of mergers and acquisitions, as well as $1.1
billion of impairment charges on product intangibles. Amounts
included in marketing and administrative expenses reflect merger
integration costs, as well as transaction and certain other costs
related to business acquisitions and divestitures. Amounts included
in research and development expenses represent in-process research
and development (“IPR&D”) impairment charges primarily related
to the company's joint venture with Supera. Amount included in
other (income) expense, net is a goodwill impairment charge related
to the joint venture with Supera. Amount included in net income
(loss) attributable to non-controlling interests represents the
portion of intangible asset and goodwill impairment charges related
to the joint venture with Supera that are attributable to
non-controlling interests.
(2) Amounts primarily include employee separation costs and
accelerated depreciation associated with facilities to be closed or
divested related to actions under the company's formal
restructuring programs.
(3) Amount included in marketing and administrative expenses
represents an additional year of expense related to the healthcare
reform fee in accordance with final regulations issued in the third
quarter by the Internal Revenue Service. Included in other (income)
expense, net is a $396 million gain on the divestiture of certain
ophthalmic products in several international markets and a $741
million net gain related to AstraZeneca's option exercise.
(4) Represents the estimated tax impact on the reconciling
items, including a net benefit of approximately $517 million
recorded in connection with AstraZeneca's option exercise, as well
as a benefit of approximately $300 million associated with a
capital loss generated in the first quarter.
MERCK & CO., INC. FRANCHISE / KEY PRODUCT
SALES (AMOUNTS IN MILLIONS) Table 3
2014
2013 % Change % Change 1Q
2Q 3Q Sep YTD 1Q
2Q 3Q Sep YTD 4Q
Full Year
3Q
Sep YTD
TOTAL
SALES (1)
$10,264 $10,934
$10,557 $31,755 $10,671
$11,010 $11,032 $32,713
$11,319 $44,033 -4 -3
PHARMACEUTICAL 8,451 9,087 9,134
26,672 8,891 9,310 9,475 27,677
9,760 37,437 -4 -4 Primary
Care and Women's Health Cardiovascular Zetia 611 717 660 1,988
629 650 662 1,941 716 2,658 2 Vytorin 361 417 369 1,146 394 417 396
1,207 436 1,643 -7 -5 Diabetes Januvia / Janumet 1,334 1,577
1,439 4,350 1,293 1,547 1,369 4,208 1,624 5,833 5 3 General
Medicine & Women's Health NuvaRing 168 178 186 531 151 171 170
492 193 686 9 8 Implanon / Nexplanon 102 119 158 379 84 102 96 282
120 403 65 34 Dulera 102 103 124 328 68 79 82 229 95 324 51 43
Follistim AQ 110 102 97 309 122 134 124 380 101 481 -22 -19
Hospital and Specialty Hepatitis PegIntron 112 103 84
300 126 142 104 372 124 496 -19 -19 Victrelis 59 46 27 132 110 116
121 347 81 428 -78 -62 HIV Isentress 390 453 412 1,255 362
412 427 1,201 442 1,643 -3 4 Acute Care Cancidas 166 156 183
505 162 163 151 477 183 660 21 6 Invanz 114 134 141 390 110 120 130
360 128 488 9 8 Noxafil 74 98 107 280 65 71 75 212 98 309 42 32
Bridion 73 82 90 245 63 69 75 206 82 288 20 19 Primaxin 71 81 91
243 84 85 88 256 79 335 4 -5 Immunology Remicade 604 607 604
1,815 549 527 574 1,651 620 2,271 5 10 Simponi 157 174 170 500 108
120 126 354 146 500 35 41 Other Cosopt / Trusopt 99 100 34
232 105 103 104 313 103 416 -68 -26
Oncology
Emend 122 144 136 402 116 135 123 373 134 507 11 8 Temodar 83 93 88
264 216 219 162 596 111 708 -46 -56
Diversified
Brands Respiratory Nasonex 312 258 261 830 385 325 297
1,008 327 1,335 -12 -18 Singulair 271 284 218 773 337 281 280 898
298 1,196 -22 -14 Clarinex 62 69 49 180 61 64 54 180 55 235 -10
Other Cozaar / Hyzaar 205 214 195 614 267 255 238 760 246
1,006 -18 -19 Arcoxia 128 141 132 400 121 121 112 354 131 484 18 13
Fosamax 123 121 114 358 137 144 140 421 139 560 -19 -15 Propecia 74
58 66 197 68 67 71 206 77 283 -7 -4 Zocor 64 69 61 194 82 74 65 221
79 301 -6 -12 Remeron 50 40 47 137 52 53 44 150 56 206 7 -8
Vaccines Gardasil 383 409 590 1,382 390 383 665 1,438
394 1,831 -11 -4 ProQuad, M-M-R II and Varivax 280 326 421 1,027
272 339 421 1,032 273 1,306 -1 RotaTeq 169 147 174 490 162 144 201
507 129 636 -14 -3 Zostavax 142 156 181 479 168 141 185 494 264 758
-2 -3 Pneumovax 23 101 102 197 400 111 108 193 412 241 653 2 -3
Other Pharmaceutical (2) 1,175 1,209 1,228 3,617
1,361 1,430 1,350 4,139 1,435 5,570 -9 -13
ANIMAL
HEALTH 813 872 885 2,569 840
851 800 2,491 871 3,362
11 3 CONSUMER CARE (3)
546
583 401 1,531 571 490 443
1,504 390 1,894 -9 2 Claritin
OTC 170 153 110 433 177 78 123 379 92 471 -11 14
Other
Revenues (4)
454 392 137 983
369 359 314 1,041 298
1,340 -56 -5 Astra 147 316 1 465 262 245 220
727 193 920 -99 -36
Sum of quarterly amounts may not equal year-to-date amounts due
to rounding.
(1) Only select products are shown.
(2) Includes Pharmaceutical products not individually shown
above. Other Vaccines sales included in Other Pharmaceutical were
$98 million, $76 million and $116 million for the first, second and
third quarters of 2014, respectively. Other Vaccines sales included
in Other Pharmaceutical were $53 million, $86 million, $127
million, and $101 million for the first, second, third, and fourth
quarters of 2013, respectively.
(3) The decrease in Consumer Care sales in the second quarter
and full year of 2013 resulted from the termination in China of
distribution arrangements and a reversal of sales previously made
to those distributors, together with associated termination
costs.
(4) Other revenues are comprised primarily of alliance revenue,
third-party manufacturing sales and miscellaneous corporate
revenues, including revenue hedging activities. On October 1, 2013,
the company divested a substantial portion of its third-party
manufacturing sales. On June 30, 2014, AstraZeneca exercised its
option to buy Merck's interest in a subsidiary and through it,
Merck's interest in Nexium and Prilosec. As a result, the company
no longer records supply sales for these products. Other revenues
in the first quarter and September YTD 2014 include $232 million of
revenue recognized in connection with the sale of U.S. Saphris
rights. In addition, Other revenues in the fourth quarter and full
year of 2013 reflect $50 million of revenue for the out-license of
a pipeline compound.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141027005422/en/
MerckMedia:Steve Cragle, 908-423-3461Lainie Keller,
908-236-5036orInvestors:Joe Romanelli, 908-423-5185Justin Holko,
908-423-5088
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024